Reply to the letters to the editor 'Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by Diwakar et al

Ann Oncol. 2015 Jan;26(1):250-251. doi: 10.1093/annonc/mdu502. Epub 2014 Oct 29.

Authors

B Schilling¹, W Sondermann², K G Griewank², E Livingstone², L Zimmer², U Hillen², D Schadendorf²

Affiliations

¹ Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen; German Cancer Consortium (DKTK), Heidelberg, Germany. Electronic address: [email protected].
² Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen; German Cancer Consortium (DKTK), Heidelberg, Germany.

PMID: 25355721
DOI: 10.1093/annonc/mdu502

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents / therapeutic use*
Female
Humans
Imidazoles / therapeutic use*
Indoles / therapeutic use*
Lymphocyte Subsets / drug effects*
Male
Melanoma / drug therapy*
Oximes / therapeutic use*
Sulfonamides / therapeutic use*

Substances

Antineoplastic Agents
Imidazoles
Indoles
Oximes
Sulfonamides